A Phase 1, Single-Administration Pharmacokinetic and Safety Study of Oral and IV Tedizolid Phosphate in Hospitalized Subjects 2 to < 12 Years Old

Trial Profile

A Phase 1, Single-Administration Pharmacokinetic and Safety Study of Oral and IV Tedizolid Phosphate in Hospitalized Subjects 2 to < 12 Years Old

Recruiting
Phase of Trial: Phase I

Latest Information Update: 06 Dec 2017

At a glance

  • Drugs Tedizolid (Primary) ; Tedizolid (Primary)
  • Indications Bacterial infections; Gram-positive infections
  • Focus Pharmacokinetics
  • Sponsors Cubist Pharmaceuticals; Merck Sharp & Dohme
  • Most Recent Events

    • 21 Sep 2017 Planned End Date changed from 27 Apr 2018 to 23 Mar 2019.
    • 21 Sep 2017 Planned primary completion date changed from 27 Apr 2018 to 23 Mar 2019.
    • 22 Feb 2017 Planned End Date changed from 1 Feb 2018 to 1 Apr 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top